BEHANDLUNG EINER HEPATITIS-DELTA-VIRUSINFEKTION MIT INTERFERON-LAMBDA

European patent · EP3957319 · In force

Register entry

Publication number
EP3957319
Application number
EP21164362
Kind
European patent with effect for Switzerland and Liechtenstein
Status
In force
Specification
Granted
Filed
Feb 17, 2017
Published
Feb 23, 2022
Granted
Dec 4, 2024
Protection ends at the latest
Feb 16, 2037
Next annual fee due
Feb 28, 2027
IPC classes
A61K 38/21 (2006.01)
A61P 1/16 (2006.01)
A61P 31/14 (2006.01)
Priority
US 201662297759 P 19.02.2016
Divided from
EP17753966
Filing language
English
Source
Swissreg

History

What the Federal Institute of Intellectual Property published about this title, newest first.

  1. Mar 1, 2026

    Change

    Published in Swissreg on 01.03.2026

  2. Oct 15, 2025

    Change

    Published in Swissreg on 15.10.2025

  3. Mar 1, 2025

    Change

    Published in Swissreg on 01.03.2025

  4. Feb 19, 2025

    Agent entered

    Representative
    MICHELI & CIE SA, 122, rue de Genève,, CP 61, 1226 Thônex

    Published in Swissreg on 19.02.2025

  5. Feb 12, 2025

    Owner

    Owner
    Eiger InnoTherapeutics, Inc., 2061 Webster Street, Palo Alto, CA 94301, USA → EIT Pharma, Inc., 11620 Wilshire Boulevard, Suite 350, Los Angeles, CA 90025, USA

    Published in Swissreg on 12.02.2025

  6. Dec 4, 2024

    Granted

    Specification status
    Non-published patent application → Granted patent
    Status of protective title
    Initiated → Active

    Published in Swissreg on 04.12.2024

Parties

Holder

EIT Pharma, Inc.

11620 Wilshire Boulevard Suite 350, Los Angeles, CA 90025, US

Agent

MICHELI & CIE SA

122, rue de Genève, CP 61, 1226 Thônex

Inventor

MARTINS, Eduardo Bruno

Palo Alto, California 94306, US

The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.